These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 21316103

  • 21. Chronic myeloid leukemia with an e13a3 BCR-ABL fusion: benign course responsive to imatinib with an RT-PCR advisory.
    Snyder DS, McMahon R, Cohen SR, Slovak ML.
    Am J Hematol; 2004 Feb; 75(2):92-5. PubMed ID: 14755375
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. [Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR].
    Qin YZ, Ruan GR, Liu YR, Li JL, Fu JY, Wang H, Chang Y, Jiang B, Jiang Q, Jiang H, Qiu JY, Chen SS, Lu DP.
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):1-5. PubMed ID: 15946498
    [Abstract] [Full Text] [Related]

  • 24. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
    DeAngelo DJ, Hochberg EP, Alyea EP, Longtine J, Lee S, Galinsky I, Parekkedon B, Ritz J, Antin JH, Stone RM, Soiffer RJ.
    Clin Cancer Res; 2004 Aug 01; 10(15):5065-71. PubMed ID: 15297408
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status.
    Frater JL, Tallman MS, Variakojis D, Druker BJ, Resta D, Riley MB, Hrisinko MA, Peterson LC.
    Am J Clin Pathol; 2003 Jun 01; 119(6):833-41. PubMed ID: 12817431
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Isolated CNS lymphoid blast crisis in a patient with imatinib-resistant chronic myelogenous leukemia: case report and review of the literature.
    Aftimos P, Nasr F.
    Leuk Res; 2009 Nov 01; 33(11):e178-80. PubMed ID: 19446330
    [No Abstract] [Full Text] [Related]

  • 30. Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib.
    Koh Y, Kim I, Yoon SS, Kim BK, Kim DY, Lee JH, Lee KH, Park E, Kim HJ, Sohn SK, Joo YD, Kim SJ, Chung J, Shin HJ, Kim SH, Kim CS, Song HS, Kim MK, Hyun MS, Ahn JS, Jung CW, Park S, Korean Society of Hematology CML working party.
    Ann Hematol; 2010 Jul 01; 89(7):725-31. PubMed ID: 20179930
    [Abstract] [Full Text] [Related]

  • 31. Major molecular response to imatinib in a patient with chronic myeloid leukemia expressing a novel form of e8a2 BCR-ABL transcript.
    Tchirkov A, Couderc JL, Périssel B, Goumy C, Regnier A, Uhrhammer N, Verrelle P, Berger M.
    Leukemia; 2006 Jan 01; 20(1):167-8. PubMed ID: 16270035
    [No Abstract] [Full Text] [Related]

  • 32. BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria.
    Branford S, Seymour JF, Grigg A, Arthur C, Rudzki Z, Lynch K, Hughes T.
    Clin Cancer Res; 2007 Dec 01; 13(23):7080-5. PubMed ID: 18056186
    [Abstract] [Full Text] [Related]

  • 33. Complete cytogenetic and molecular response after imatinib treatment for chronic myeloid leukemia in a patient with atypical karyotype and BCR-ABL b2a3 transcript.
    Pienkowska-Grela B, Woroniecka R, Solarska I, Kos K, Pastwińska A, Konopka L, Majewski M.
    Cancer Genet Cytogenet; 2007 Apr 15; 174(2):111-5. PubMed ID: 17452251
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Sustained clinical remission despite suboptimal molecular response to imatinib in e1a2 BCR-ABL chronic myeloid leukemia.
    Langabeer SE, Crampe M, Haslam K, Kelly J, Cahill MR.
    Leuk Res; 2010 Jul 15; 34(7):e176-7. PubMed ID: 20153526
    [No Abstract] [Full Text] [Related]

  • 37. [Detection and quantification of BCR-ABL transcripts in patients with chronic myeloid leukemia by real-time quantitative reverse transcriptase polymerase chain reaction].
    Xing W, Gu BW, Zhu YM, Jiang CL, Zhao RH, Wang AH, Sun HP, Li JM, Shen ZX, Chen Z, Chen SJ.
    Zhonghua Yi Xue Za Zhi; 2005 Feb 23; 85(7):453-7. PubMed ID: 15854550
    [Abstract] [Full Text] [Related]

  • 38. New-age drug meets resistance.
    McCormick F.
    Nature; 2001 Jul 19; 412(6844):281-2. PubMed ID: 11460142
    [No Abstract] [Full Text] [Related]

  • 39. Residual disease in chronic myeloid leukemia after induction of molecular remission.
    Lange T, Niederwieser DW, Deininger MW.
    N Engl J Med; 2003 Oct 09; 349(15):1483-4. PubMed ID: 14534349
    [No Abstract] [Full Text] [Related]

  • 40. Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.
    Wei Y, Hardling M, Olsson B, Hezaveh R, Ricksten A, Stockelberg D, Wadenvik H.
    Ann Hematol; 2006 Dec 09; 85(12):841-7. PubMed ID: 17006667
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.